how long is compounded semaglutide good for FDA Warns on Certain Forms of Compound Semaglutide Storage & Shelf

Table of Contents What Is Retatrutide and Its Current Development Status in the UK Risks of Sourcing Unregulated Peptides Online MHRA Guidance on Unlicensed Weight Loss Treatments Approved Alternatives Available Through NHS and Private Clinics How to Speak to a UK Doctor About Emerging Weight Loss Options Scientific References Frequently Asked Questions What Is Retatrutide and Its Current Development Status in the UK Retatrutide is an investigational triple incretin receptor agonist (GLP-1, GIP, and glucagon) developed by Eli Lilly that remains in Phase 3 trials and holds no MHRA marketing authorisation as of mid-2025

For sourcing guidance, see where to buy peptides in 2026

It is a common choice for reconstituting lyophilised research compounds and preparing peptide solutions in a controlled setting

Is this product pharmaceutical grade?

This product does not contain synthetic GLP-1 and is not a GLP-1 agonist drug

By understanding the nuances of these injectable medications, they can make informed decisions that align with their health and aesthetic goals